Tradestie Institutional Equity Comparison Engine
NVS vs GILD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
GILD Overall Edge
GILD Captures Institutional Edge (4โ0 Pillars ยท 4โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Gilead Sciences Inc (GILD) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NVS trades at 16.2x Forward P/E with 34.0% operating margin (+4.7% YoY revenue) versus GILD at 16.6x Forward P/E and 38.2% operating margin (+6.8% YoY). In options structure, NVS sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro) against GILD sits in SURGE (10th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
GILD
NVS 16.2x vs GILD 16.6x Fwd P/E
Growth & Margin Winner
GILD
Op Margin 34.0% vs 38.2% ยท YoY +4.7% vs +6.8%
Momentum & Technical Winner
GILD
1Y +22.5% vs +35.1% ยท 52W Pos 81% vs 88%
Options & Structure Winner
GILD
UNCLASSIFIED (6th %ile IV) vs SURGE (10th %ile IV)
NVS
NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap
$302.9B
1M Return
+7.28%
1Y Return
+22.5%
Forward P/E
16.2x
Unified AI Score
41.5 / 100
SELL
Tech 29.0
Fund 38.0
Flow 50.0
Mom 21.1
GILD
NASDAQ
Gilead Sciences Inc
Biological Products, (No Disgnostic Substances)
$169.09
+0.6% 1D
Market Cap
$208.3B
1M Return
+8.26%
1Y Return
+35.06%
Forward P/E
16.6x
Unified AI Score
40.1 / 100
SELL
Tech 24.0
Fund 47.0
Flow 70.0
Mom 46.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NVS +22.5%
GILD +35.06%
Spread: +12.56 pp (GILD Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
NVS TTM Op. Margin: 34.0%
GILD TTM Op. Margin: 38.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs GILD. Trailing 12-month operating profitability (NVS 34.0% vs GILD 38.2%) and valuation multiples (NVS 16.2x vs GILD 16.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NVS | GILD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $302.9B | $208.3B | Larger Scale | NVS |
| Trailing P/E Ratio Valuation | 30.6x | 17.0x | Lower Multiple | GILD |
| Forward P/E Ratio Valuation | 16.2x | 16.6x | Lower Multiple | NVS |
| Revenue Growth (YoY) Growth | +4.7% | +6.8% | Higher Growth | GILD |
| Operating Margin (TTM) Profitability | 34.0% | 38.2% | Higher Margin | GILD |
| Net Profit Margin Profitability | 17.5% | -12.5% | Higher Margin | NVS |
| Return on Equity (ROE) Capital Efficiency | 24.3% | -22.4% | Higher ROE | NVS |
| 52-Week Range Position Momentum | 81% ($123โ$170) | 88% ($117โ$177) | Stronger Trend | GILD |
| Beta / 30D Volatility Risk Regime | 0.31ฮฒ ยท 27% Vol | 0.34ฮฒ ยท 32% Vol | Lower Realized Risk | NVS |
| Unified Institutional Score Composite Signal | 41.5 / 100 (SELL) | 40.1 / 100 (SELL) | Higher Composite | NVS |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NVS vs GILD Buy Guide
NVS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
GILD
SURGE
7d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
10th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NVS nor GILD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.